S100A2 activation promotes interstitial fibrosis in kidneys by FoxO1-mediated epithelial-mesenchymal transition.

IF 5.3 2区 医学 Q2 CELL BIOLOGY
Xuejia Yang, Fan Zheng, Penghua Yan, Xueting Liu, Xuanwen Chen, Xinyu Du, Yin Zhang, Peilei Wang, Chaosheng Chen, Hong Lu, Yongheng Bai
{"title":"S100A2 activation promotes interstitial fibrosis in kidneys by FoxO1-mediated epithelial-mesenchymal transition.","authors":"Xuejia Yang, Fan Zheng, Penghua Yan, Xueting Liu, Xuanwen Chen, Xinyu Du, Yin Zhang, Peilei Wang, Chaosheng Chen, Hong Lu, Yongheng Bai","doi":"10.1007/s10565-024-09929-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Renal interstitial fibrosis (RIF) is a common feature of chronic kidney diseases (CKD), with epithelial-mesenchymal transition (EMT) being one of its important mechanisms. S100A2 is a protein associated with cell proliferation and differentiation, but its specific functions and molecular mechanisms in RIF remain to be determined.</p><p><strong>Methods: </strong>S100A2 levels were evaluated in three mouse models, including unilateral ureteral obstruction (UUO), ischemia-reperfusion injury (IRI), and aristolochic acid nephropathy (AAN), as well as in TGF-β1- treated HK-2 cells and in kidney tissue samples. Furthermore, the role of S100A2 and its interaction with FoxO1 was investigated using RT-qPCR, immunoblotting, immunofluorescence staining, co-immunoprecipitation (Co-IP), transcriptome sequencing, and gain- or loss-of-function approaches in vitro.</p><p><strong>Results: </strong>Elevated expression levels of S100A2 were observed in three mouse models and TGF-β1-treated HK2 cells, as well as in kidney tissue samples. Following siRNA silencing of S100A2, exposure to TGF-β1 in cultured HK-2 cells suppressed EMT process and extracellular matrix (ECM) accumulation. Conversely, Overexpression of S100A2 induced EMT and ECM deposition. Notably, we identified that S100A2-mediated EMT depends on FoxO1. Immunofluorescence staining indicated that S100A2 and FoxO1 colocalized in the nucleus and cytoplasm, and their interaction was verified in Co-IP assay. S100A2 knockdown decreased TGF-β1-induced phosphorylation of FoxO1 and increased its protein expression, whereas S100A2 overexpression hampered FoxO1 activation. Furthermore, pharmacological blockade of FoxO1 rescued the induction of TGF-β1 on EMT and ECM deposition in S100A2 siRNA-treated cells.</p><p><strong>Conclusion: </strong>S100A2 activation exacerbates interstitial fibrosis in kidneys by facilitating FoxO1-mediated EMT.</p>","PeriodicalId":9672,"journal":{"name":"Cell Biology and Toxicology","volume":"40 1","pages":"86"},"PeriodicalIF":5.3000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464619/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Biology and Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10565-024-09929-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Renal interstitial fibrosis (RIF) is a common feature of chronic kidney diseases (CKD), with epithelial-mesenchymal transition (EMT) being one of its important mechanisms. S100A2 is a protein associated with cell proliferation and differentiation, but its specific functions and molecular mechanisms in RIF remain to be determined.

Methods: S100A2 levels were evaluated in three mouse models, including unilateral ureteral obstruction (UUO), ischemia-reperfusion injury (IRI), and aristolochic acid nephropathy (AAN), as well as in TGF-β1- treated HK-2 cells and in kidney tissue samples. Furthermore, the role of S100A2 and its interaction with FoxO1 was investigated using RT-qPCR, immunoblotting, immunofluorescence staining, co-immunoprecipitation (Co-IP), transcriptome sequencing, and gain- or loss-of-function approaches in vitro.

Results: Elevated expression levels of S100A2 were observed in three mouse models and TGF-β1-treated HK2 cells, as well as in kidney tissue samples. Following siRNA silencing of S100A2, exposure to TGF-β1 in cultured HK-2 cells suppressed EMT process and extracellular matrix (ECM) accumulation. Conversely, Overexpression of S100A2 induced EMT and ECM deposition. Notably, we identified that S100A2-mediated EMT depends on FoxO1. Immunofluorescence staining indicated that S100A2 and FoxO1 colocalized in the nucleus and cytoplasm, and their interaction was verified in Co-IP assay. S100A2 knockdown decreased TGF-β1-induced phosphorylation of FoxO1 and increased its protein expression, whereas S100A2 overexpression hampered FoxO1 activation. Furthermore, pharmacological blockade of FoxO1 rescued the induction of TGF-β1 on EMT and ECM deposition in S100A2 siRNA-treated cells.

Conclusion: S100A2 activation exacerbates interstitial fibrosis in kidneys by facilitating FoxO1-mediated EMT.

S100A2 激活通过 FoxO1 介导的上皮-间质转化促进肾脏间质纤维化。
背景:肾间质纤维化(RIF)是慢性肾脏病(CKD)的常见特征,上皮-间质转化(EMT)是其重要机制之一。S100A2是一种与细胞增殖和分化相关的蛋白质,但它在RIF中的具体功能和分子机制仍有待确定:方法:在三种小鼠模型(包括单侧输尿管梗阻(UUO)、缺血再灌注损伤(IRI)和马兜铃酸肾病(AAN))以及经 TGF-β1 处理的 HK-2 细胞和肾组织样本中评估了 S100A2 的水平。此外,研究人员还利用 RT-qPCR、免疫印迹、免疫荧光染色、共免疫沉淀(Co-IP)、转录组测序以及体外功能增益或缺失方法研究了 S100A2 的作用及其与 FoxO1 的相互作用:结果:在三种小鼠模型和经 TGF-β1 处理的 HK2 细胞以及肾组织样本中观察到 S100A2 表达水平升高。siRNA 沉默 S100A2 后,培养的 HK-2 细胞暴露于 TGF-β1 会抑制 EMT 过程和细胞外基质(ECM)的积累。相反,过表达 S100A2 会诱导 EMT 和 ECM 沉积。值得注意的是,我们发现 S100A2 介导的 EMT 依赖于 FoxO1。免疫荧光染色表明,S100A2 和 FoxO1 在细胞核和细胞质中共定位,它们之间的相互作用在 Co-IP 试验中得到了验证。敲除 S100A2 可减少 TGF-β1 诱导的 FoxO1 磷酸化并增加其蛋白表达,而过表达 S100A2 则会阻碍 FoxO1 的激活。此外,药理阻断 FoxO1 可缓解 TGF-β1 对 S100A2 siRNA 处理细胞的 EMT 和 ECM 沉积的诱导作用:结论:S100A2 的激活通过促进 FoxO1 介导的 EMT 而加剧肾脏间质纤维化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cell Biology and Toxicology
Cell Biology and Toxicology 生物-毒理学
CiteScore
9.90
自引率
4.90%
发文量
101
审稿时长
>12 weeks
期刊介绍: Cell Biology and Toxicology (CBT) is an international journal focused on clinical and translational research with an emphasis on molecular and cell biology, genetic and epigenetic heterogeneity, drug discovery and development, and molecular pharmacology and toxicology. CBT has a disease-specific scope prioritizing publications on gene and protein-based regulation, intracellular signaling pathway dysfunction, cell type-specific function, and systems in biomedicine in drug discovery and development. CBT publishes original articles with outstanding, innovative and significant findings, important reviews on recent research advances and issues of high current interest, opinion articles of leading edge science, and rapid communication or reports, on molecular mechanisms and therapies in diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信